Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality
- PMID: 28573191
- PMCID: PMC5441987
- DOI: 10.1097/TXD.0000000000000673
Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality
Abstract
Background: Invasive fungal infections remain a leading cause of morbidity and mortality among liver transplant recipients (LTRs). In this patient population, invasive Candida infections (ICIs) account for the large majority of cases. To date, only small studies and case-series analysing clinical presentation and risk factors for mortality in LTRs with ICIs are available.
Methods: We performed a retrospective multicenter multinational study in 10 centers in Europe and Brazil. All consecutive LTRs developing ICIs during the period January 2011 to December 2013 were included in the study.
Results: A total of 42 LTRs were included. Median age was 52.5 years, and 78.6% of patients were men. Viral hepatitis was the most common cause for liver transplantation (42.9%). Candidemia represented the majority of cases (24, 57.1%), followed by intra-abdominal candidiasis (18, 42.9%). Overall 30-day mortality was 23.8%, with higher mortality in patients with candidemia compared with intra-abdominal candidiasis (37.5% vs 5.6%, P = 0.02). Multivariate analysis showed candidemia to be a risk factor associated with mortality among LTRs presenting ICIs (odds ratio, 11.86; 95% confidence interval, 1.5-280; P = 0.01). Candida albicans represented the most common isolate (59.5%). High rates of antifungal resistances were found, with 16.7% and 4.8% of isolates displaying resistance to azoles and caspofungin, respectively.
Conclusions: Our study confirms the occurrence of high mortality rates in LTRs developing ICIs. Mortality rates varied according to the type of infection, with candidemia representing a risk factor for mortality. The high rates of antifungal resistance should be considered in the choice of the empiric antifungal regimen.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Candidemia in solid organ transplant recipients in Spain: Epidemiological trends and determinants of outcome.Transpl Infect Dis. 2019 Dec;21(6):e13195. doi: 10.1111/tid.13195. Epub 2019 Oct 26. Transpl Infect Dis. 2019. PMID: 31610077
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study.Intensive Care Med. 2017 Apr;43(4):509-518. doi: 10.1007/s00134-017-4717-0. Epub 2017 Mar 7. Intensive Care Med. 2017. PMID: 28271321
-
Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).Crit Care Med. 2009 May;37(5):1612-8. doi: 10.1097/CCM.0b013e31819efac0. Crit Care Med. 2009. PMID: 19325476
-
Candidemia and invasive candidiasis in adults: A narrative review.Eur J Intern Med. 2016 Oct;34:21-28. doi: 10.1016/j.ejim.2016.06.029. Epub 2016 Jul 7. Eur J Intern Med. 2016. PMID: 27394927 Review.
Cited by
-
Two New 1,3,4-Oxadiazoles With Effective Antifungal Activity Against Candida albicans.Front Microbiol. 2019 Sep 12;10:2130. doi: 10.3389/fmicb.2019.02130. eCollection 2019. Front Microbiol. 2019. PMID: 31572335 Free PMC article.
-
Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions.World J Gastroenterol. 2018 Oct 14;24(38):4311-4329. doi: 10.3748/wjg.v24.i38.4311. World J Gastroenterol. 2018. PMID: 30344417 Free PMC article. Review.
-
Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.Eur J Clin Pharmacol. 2018 Nov;74(11):1449-1459. doi: 10.1007/s00228-018-2526-1. Epub 2018 Jul 21. Eur J Clin Pharmacol. 2018. PMID: 30032414
-
Invasive Fungal Infections after Liver Transplantation.J Clin Med. 2023 Apr 30;12(9):3238. doi: 10.3390/jcm12093238. J Clin Med. 2023. PMID: 37176678 Free PMC article. Review.
-
Candidemia in critically ill immunocompromised patients: report of a retrospective multicenter cohort study.Ann Intensive Care. 2019 Jun 3;9(1):62. doi: 10.1186/s13613-019-0539-2. Ann Intensive Care. 2019. PMID: 31161475 Free PMC article.
References
-
- Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101–1111. - PubMed
-
- Yang CH, He XS, Chen J, et al. Fungal infection in patients after liver transplantation in years 2003 to 2012. Ann Transplant. 2012;17:59–63. - PubMed
-
- Rabkin JM, Oroloff SL, Corless CL, et al. Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg. 2000;179:426–430. - PubMed
-
- Liu X, Ling Z, Li L, et al. Invasive fungal infections in liver transplantation. Int J Infect Dis. 2011;15:e298–e304. - PubMed
-
- Winston DJ, Limaye AP, Pelletier S, et al. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant. 2014;14:2758–2764. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources